Abstract
Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P=0.017), interferon-gamma (P=0.010), and tumor necrosis factor-alpha (P=0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.
Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042.
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.
Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gmbacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
Druker BJ . Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 90: 1–30.
Reuben JM, Lee B-N, Johnson H, Fritsche H, Kantarjian HM, Talpaz M . Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res 2000; 6: 1671–1677.
Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukemia patients in complete hematological remission. Brit J Haematol 2001; 113: 136–142.
Gao H, Lee B-N, Donato NJ, Talpaz M, Reuben JM . Imatinib (Gleevec, STI-571) suppresses cytokine production by normal T cells activated through T-cell receptor (TCR) signaling. J Allergy Clin Immunol 2005; 105: S221.
Cwynarski K, Laylor R, Macchiarulo E, Goldman JM, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.
Joss A, Akdis M, Faith A, Blaser K, Akdis CA . IL-10 directly acts on T cells by specifically altering the CD28 co-stimulatory pathway. Eur J Immunol 2000; 30: 1683–1690.
Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU . Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069.
Nylander S, Kalies I . Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. J Immunol Methods 1999; 224: 69–76.
Lee B-N, Duvic M, Tang C-K, Buenos-Ramos C, Estrov Z, Reuben JM . Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6: 79–84.
Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–942.
Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM . Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985; 313: 318–320.
Garcia C, Briggs C, Zhang L, Guan L, Gabriel JL, Rogers TJ . Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B. Immunology 1998; 94: 160–166.
Erickson S, Sangfelt O, Castro J, Heyman M, Einhorn S, Grander D . Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin-2 induced changes in cell cycle-regulatory proteins. Cell Growth Differ 1999; 10: 575–582.
Julius M, Maroun C, Haughn L . Distinct roles for CD4 and CD8 coreceptors in antigen receptor signaling. Immunol Today 1993; 14: 177–183.
Maroun CR, Julius M . Distinct roles for CD4 and CD8 as co-receptors in T cell receptor signalling. Eur J Immunol 1994; 24: 959–966.
Ravichandran KS, Burakoff SJ . Evidence for differential intracellular signaling via CD4 and CD8 molecules. J Exp Med 1994; 179: 727–732.
Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.
Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.
Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J et al. Development of Varicella–Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976–980.
Yasukawa M, Yakushijin Y, Fujita S . Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones. Clin Immunol Immunopathol 1996; 78: 70–76.
Yasukawa M, Ohminami H, Yakushijin Y, Arai J, Hasegawa A, Ishida Y et al. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. J Immunol 1999; 162: 6100–6106.
Yotnda P, Huseyin F, Garcia-Pons F, Garcia Z, Gourru G, Vernant J-P et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290–2296.
Whittington R, Faulds D . Interleukin-2: a review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446–514.
Acknowledgements
We thank clinical and research nurses Shela M Broussard, Marilyn S Elopre, and Vilma T Lopez, whose perseverance made it possible to recruit the patients for this study. We also thank De-Yu Shen for technical assistance and Clement Nzegwu and Joanne Black for maintaining the patient database. This work was supported in part by grants from the National Aeronautics and Space Administration NAG 9-1454 01 (JMR) and the Leukemia-Lymphoma Society (NJD).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gao, H., Lee, BN., Talpaz, M. et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19, 1905–1911 (2005). https://doi.org/10.1038/sj.leu.2403933
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403933
Keywords
This article is cited by
-
Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α
Journal of Translational Medicine (2020)
-
Immunological off-target effects of imatinib
Nature Reviews Clinical Oncology (2016)
-
A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia
Advances in Difference Equations (2012)
-
The secret ally: immunostimulation by anticancer drugs
Nature Reviews Drug Discovery (2012)
-
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells
Breast Cancer Research and Treatment (2012)